2-deoxy-D-glucose (2-DG) has recently been approved to treat moderate to severe COVID-19 patients in India. Here we discuss whether this is a well-thought-out step towards the long-term management of COVID-19 or a decision taken at the spur of the moment. 2-DG, an anticancer drug, also has immunomodulatory functions. Several studies have shown 2-DG to inhibit viral replication and cytokine storm. However, these findings are mostly on cells and animal models. The clinical trial that has become the basis of the approval of this drug in India is yet to be peer-reviewed and has not explicitly addressed several concerns, nor has it established its claim of faster efficacy with rigorous statistics and safety profile. Even though 2-DG shows a lot of promise in COVID-19 treatment, its approval seems rather premature, which may prove to be more harmful than beneficial in the long run.
Ghosh, Ritwik; Roy, Dipayan; Chatterjee, Subhankar; and Benito-León, Julián
"2-deoxy-D-Glucose as India’s Response to COVID-19: A Commitment or Conceit?,"
Journal of Community Hospital Internal Medicine Perspectives: Vol. 12:
3, Article 9.
Available at: https://scholarlycommons.gbmc.org/jchimp/vol12/iss3/9